Imugene

IMU.AXPhase 2

Imugene is focused on developing next-generation immunotherapies that aim to stimulate the body's immune system to fight cancer. Its core technology platforms include oncolytic virotherapy (CF33), B-cell immunotherapy (HER-Vaxx), and checkpoint inhibitor therapies. The company has multiple candidates in clinical development, primarily targeting gastrointestinal cancers and other solid tumors, and operates through strategic collaborations with leading cancer research institutions.

Market Cap

$37.8M

Employees

11-50

Focus

Biotech

IMU.AX · Stock Price

USD 0.1515.93 (-99.07%)

Historical price data

AI Company Overview

Technology Platform

Develops novel cancer immunotherapies based on three core platforms: an oncolytic virotherapy platform (CF33), a B-cell immunotherapy vaccine platform (HER-Vaxx), and a checkpoint immunotherapy vaccine platform (PD1-Vaxx).

Pipeline Snapshot

7 drugs in pipeline

Drug	Indication	Stage
IMU-131 + Ramucirumab plus Paclitaxel + Pembrolizumab	Gastric Cancer	Phase 2
IMU-131 + Cisplatin and either Fluorouracil (5-FU) or Capecitabine or Oxaliplati...	Gastrointestinal Neoplasms	Phase 1/2
Azer-cel + Fludarabine + Cyclophosphamide + IL-2	Non-Hodgkin Lymphoma	Phase 1
CF33-hNIS + Pembrolizumab + Modified FOLFOX	Solid Tumor	Phase 1
IMU-201 (administered as PD1-Vaxx) - Regimen 1 + IMU-201 (administered as PD1-Va...	Non Small Cell Lung Cancer	Phase 1

Opportunities

Significant growth opportunity lies in demonstrating clinical proof-of-concept for its novel platforms, particularly the CF33 oncolytic virus in checkpoint inhibitor refractory cancers.

Positive data could lead to lucrative partnership deals or buyout interest from larger pharma.

The vaccine-based approaches also offer potential cost and accessibility advantages in global markets.

Risk Factors

High clinical development risk as all programs are in early stages.

Heavy reliance on dilutive equity financing creates shareholder dilution risk.

Faces intense competition from well-established, deep-pocketed pharmaceutical companies in the immuno-oncology space.

Competitive Landscape

Competes with major pharma in immuno-oncology (e.g., Merck, BMS, Roche) and smaller biotechs in oncolytic virotherapy. Differentiation is based on its novel CF33 virus backbone, its strategy to stimulate a polyclonal endogenous immune response via vaccination, and a diversified pipeline targeting multiple mechanisms.